NelsonKEClementsMLMiottiPCohnSPolkBF. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med1988; 109: 383–8.
2.
LaneHCMasurHEdgarLCWhalenGRookAFauciAS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med1983; 309: 453–8.
3.
HuangKLRubenFLRenaldoCRKingsleyLLyterDWHoM. Antibody responses after influenza and pneumococcal immunizations in HIV-infected homosexual men. JAMA1987; 257: 2047–50.
4.
MiottiPGNelsonKEDallalettaGAFarzadeganHMargolickJClementsML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA1989; 262: 779–83.
5.
RagniMVRubenFLWinkilsteinASperoJABontempFALewisJH. Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotrope virus type III) infection. J Lab Clin Med1987; 109: 545–9.
6.
RedfieldRRWrightDCJamesWDDisseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med1987; 316: 673–6.
7.
Immunization Practices Advisory Committee.Prevention and control of influenza. MMWR1989; 38: 297–31.
8.
GianniniAJHouserWLLoiselleRHAntimanic effects of verapamil. Am J Psychiatry1984; 141: 1602–3.
9.
CrowTJ. Molecular pathology of schizophrenia: More than one disease process?Br Med J1980; 280: 66–88.
10.
FerrierINRobertsJWCrowTJReduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci1983; 33: 475–82.
11.
GouldRJMurphyKMMReynoldsIJAntischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci1983; 80: 5122–5.
12.
KudoY. A double-blind comparison of pimozide with carpipramine in schizophrenic patients. Acta Psychiatr Belg1972; 72: 685–97.
13.
LapierreYD. A controlled study of penfluridol in the treatment of chronic schizophrenia. Am J Psychiatry1978; 135: 956–9.
14.
KolivakisTAzianHKingstoneE. A double blind comparison of pimozide and chlorpromazine in the maintenance of chronic schizophrenic patients. Curr Ther Res1974; 16: 998–1004.
15.
HaasSBeckmannH. Pimozide versus haloperidol in acute schizophrenia. A double-blind controlled study. Pharmacopsychiatry1982; 15: 70–4.
16.
LapierreYDLavalleJ. Pimozide and the social behaviors of schizophrenics. Curr Ther Res1975; 18: 181–8.
17.
FrangosHZissisNPLeontopoulusIDouble-blind therapeutic evaluation of fluspirilene with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatr Scand1978; 57: 436–46.
18.
FlaimSFBrannanMDSurgartSCGleasonMMMuschekLD. Neuroleptic drugs attenuate calcium influx and tension development in rabbit thoracic aorta: Effects of pimozide, penfluridol, chlorpromazine, and haloperidol. Proc Natl Acad Sci1985; 82: 1237–41.
19.
CroninMJ. Some calcium and lysosome antagonists inhibit 3H-spiperone binding to the porcine anterior pituitary. Life Sci1982; 30: 1385–9.
20.
GrospietachGFenskeMKonigAEffects of the uterine relaxant fenoterol and the calcium antagonist verapamil on plasma prolactin concentrations in mid-pregnancy. IRCS Med Sci1979; 7: 6.
21.
GluskinLEStrasbergBShahJH. Verapamil-induced hyperprolactinemia and galactorrhea. Ann Intern Med1981; 95: 66–7.
22.
JohnsonCESteinslandOSScriabineA. Dopamine antagonist effect of verapamil on isolated perfused rabbit ear artery. J Pharmacol Exp Ther1983; 226: 802–5.
23.
WalshTLLavensteinBLicameleWLCalcium antagonism in treatment of Tourette's disorder. Am J Psychiatry1986; 143: 1467–8.
24.
NurnbergerJSimmons-AllingS. Mediation of “calcium antagonist” effects by dopamine receptor blockade. Am J Psychiatry1987; 144: 966–7.
25.
MiddlemissDNSpeddingM. A functional correlate for the dihydropyridine binding site in rat brain. Nature1985; 314: 94–6.
26.
ThayerSAWelcomeMChhabraAEffects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol1985; 34: 175–80.
27.
TourjmanSVBloomDMNairNPV. Verapamil in the treatment of chronic schizophrenia. Psychopharmacol Bull1987; 23: 227–9.
28.
SchepelernSKosterA. Verapamil in treatment of severe schizophrenia. Acta Psychiatr Scand1987; 75: 557–8.
29.
ReiterSAdlerLAngristBPeselowERotrosenJ. Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patiente. J Clin Psychiatry1989; 50: 26–7.
30.
PickarDWolkowitzOMDoranAR. Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch Gen Psychiatry1987; 44: 113–8.
31.
GrebbJASheltonRCTaylorEHA negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia. Biol Psychiatry1986; 21: 691–4.
32.
PriceWAPascarziGA. Use of verapamil to treat negative symptoms in schizophrenia (letter). J Clin Psychopharmacol1987; 7: 357.
33.
PriceWA. Antipsychotic effects of verapamil in schizophrenia. Hillside J Clin Psychiatry1987; 9: 225–30.
34.
BommaritoAAHeinzelmannMJBoysenDA. A new approach to the management of obstructed feeding tubes. Nutr Clin Pract1989; 4: 111–4.
35.
AltmanECutieA. Compatibility of enteral products with commonly employed drug additives. Nutr Support Serv1984; 12 (4):8–17.
36.
Haynes-JohnsonV. Tube feeding complications: Causes, prevention, and therapy. Nutr Support Serv1986; 6 (3):17–24.
37.
IrwinMMOpenbrierDR. Feeding ventilated patients safely. Am J Nurs1985; 5: 544–6.
38.
MethenyNEisenbergPMcSweeneyM. Effect of feeding tube properties and three irrigants on clogging rates. Nurs Res1988; 37 (3): 165–9.
